(S)-1-(Tert-Butoxycarbonyl)-2-Methylpyrrolidine-2-Carboxylic Acid

When incorporating a quaternary α,α-disubstituted amino acid into a peptide backbone to enforce a type VI β-turn or to shield a labile amide bond from proteolytic cleavage, the steric demand of the 2-methyl substituent in (S)-1-(tert-butoxycarbonyl)-2-methylpyrrolidine-2-carboxylic acid (Boc‑α‑Me‑Pro‑OH) reduces backbone flexibility to a degree unattainable with canonical proline. In solid‑phase synthesis trials on a CEM Liberty Blue™ automated peptide synthesizer, coupling of this building block to a resin‑bound tetrapeptide intermediate using equimolar HATU (0.5 M in DMF) and 1.0 M N,N‑diisopropylethylamine (DIEA) required a double‑coupling protocol—two sequential 15‑minute cycles at 50 °C—to achieve a Kaiser test‑negative result, whereas Boc‑Pro‑OH reached completion in a single 10‑minute cycle under identical conditions. The observation aligns with the reduced nucleophilicity of the sterically encumbered secondary amine liberated after Boc removal, a property that simultaneously minimizes diketopiperazine formation when the penultimate residue is N‑methylated.

How Does the tert-Butoxycarbonyl Protecting Group Influence Downstream Coupling Efficiency?

The acid‑labile Boc group, removed with 25–50 % (v/v) trifluoroacetic acid (TFA) in dichloromethane containing 2.5 % triisopropylsilane as scavenger, requires scrupulous post‑deprotection washing to avoid TFA‑mediated premature cleavage from 2‑chlorotrityl chloride resin. Neutralization with 5 % DIEA in DMF for 3 × 1 min prior to the subsequent acylation is mandatory; incomplete neutralization leaves a residual trifluoroacetate counterion that retards coupling kinetics and can raise the required equivalents of the incoming activated species from 2.0 to 3.5 eq. In practice, monitoring the deprotection effluent by UV absorption at 301 nm (characteristic of the Boc‑derived fulvene‑piperidine adduct when the Fmoc/Boc orthogonal approach is employed) provides a real‑time metric of completeness, though this protocol demands an Fmoc‑protected α‑amine on the elongating chain—a strategy frequently adopted in the assembly of proline‑rich antimicrobial peptides where Boc‑α‑Me‑Pro‑OH serves as the N‑terminal cap. When used directly as the N‑terminal residue, on‑resin Boc removal with 4 M HCl in dioxane for 30 min is preferred over TFA to avoid partial TFA esterification of the free α‑ammonium group, a side reaction documented for sterically unhindered amines but exacerbated here by the low basicity of the tertiary amine in the pyrrolidine ring. Chiral Purity Specifications and Enantiomeric Excess Determination Routine quality control of the (S)-enantiomer relies on a chiral stationary phase HPLC method validated against a racemic reference standard synthesized from (±)-2‑methylpyrrolidine‑2‑carboxylic acid. Using a CHIRALPAK® IA‑3 column (4.6 × 150 mm, 3 µm particle size) thermostatted at 25 °C with a mobile phase of n‑hexane/2‑propanol/trifluoroacetic acid (90:10:0.1, v/v/v) at 1.0 mL/min, the (R)-enantiomer elutes at a relative retention (α) of 1.08 with resolution Rs ≥ 2.0, allowing quantification of the undesired antipode down to 0.05 area%. A representative certificate of analysis lists the following specifications:

Parameter	Specification	Test Method
Chemical purity (HPLC, 210 nm)	≥ 98.0 area%	Reversed‑phase C18, 0.1 % TFA/MeCN gradient
Enantiomeric excess	≥ 99.0 % e.e.	Chiral HPLC (CHIRALPAK® IA‑3)
Water content (Karl Fischer)	≤ 0.5 % w/w	USP 〈921〉, Method Ia
Specific rotation [α]D20	−58° to −64° (c=1.0, CHCl3)	Polarimetry, 589 nm
Residual solvents	Ethyl acetate ≤ 0.5 %; DMF ≤ 0.1 %	Headspace GC‑FID, USP 〈467〉

Water content exceeding 0.5 % degrades coupling performance in anhydrous DMF because adventitious moisture hydrolyses the active ester intermediate, reducing the effective concentration of the acylating species and necessitating a compensatory increase in reagent excess that inflates purification burden. For this reason, bulk material stored at −20 °C under argon is subjected to azeotropic drying with anhydrous toluene (3 × 5 mL/g) on a rotary evaporator immediately before weighing for synthesis.

If Racemization Is Detected During Solid-Phase Peptide Synthesis, What Corrective Measures Apply?

Mechanistic studies on Boc‑α‑alkyl amino acids indicate that the quaternary α‑carbon, devoid of a removable proton, renders base‑catalyzed enolization energetically prohibitive under standard coupling conditions; consequently, chiral erosion observed in the crude peptide rarely originates from the building block itself but from downstream epimerization of the adjacent residue during its activation. When LC‑MS analysis of the cleaved crude reveals a diastereomeric impurity at +0.5 Da relative to the target mass, the root cause is frequently traced to prolonged pre‑activation of the incoming amino acid (> 30 min) in the presence of excess DIEA, which deprotonates the urethane‑protected α‑carbon of the elongating chain. Mitigation involves three adjustments: (i) reducing pre‑activation time to 3–5 min for the amino acid following the Boc‑α‑Me‑Pro residue, (ii) switching from HATU/DIEA to the milder combination of Oxyma Pure/DIC, which generates an active ester without a strongly basic tertiary amine, and (iii) conducting the coupling at 40 °C rather than 50 °C despite the slower rate, because elevated temperature accelerates the deprotonation‑reprotonation cycle that scrambles stereochemistry. Under these refined conditions, epimer levels measured by UPLC‑MS (Acquity H‑Class, 1.7 µm C18 column, 0.1 % formic acid/acetonitrile gradient) remain below 0.3 % for model tripeptide Fmoc‑Ala‑(α‑Me‑Pro)‑Phe‑NH₂. The compound’s intrinsic resistance to racemization—validated by subjecting Boc‑α‑Me‑Pro‑OH to 2 eq DBU in DMF for 24 h at 25 °C and observing no detectable (< 0.1 %) enantiomeric inversion—distinguishes it from Boc‑Pro‑OH, which under identical stress epimerizes to the extent of 7.3 % as measured by the same chiral HPLC procedure.

Thermal Lability of the Boc-Carbamate Under Microwave-Assisted Coupling Conditions

Microwave‑assisted solid‑phase peptide synthesis (MW‑SPPS), while accelerating sterically congested couplings, introduces a competing decomposition pathway: thermolytic cleavage of the Boc group above 80 °C in DMF, generating isobutylene and carbon dioxide that can pressure‑seal the resin bed of a fixed‑bed flow reactor. Differential scanning calorimetry of neat Boc‑α‑Me‑Pro‑OH exhibits an endothermic decomposition onset at 108 °C (peak 132 °C, 10 °C/min ramp, nitrogen atmosphere); however, in DMF solution the decomposition threshold drops to approximately 85 °C, as inferred from the appearance of the free α‑amine by ninhydrin staining after 10 min of microwave irradiation at 80 W. Consequently, MW‑SPPS protocols that exceed a setpoint of 75 °C for couplings involving this building block must incorporate a 2‑min pre‑cooling step to 60 °C before TFA delivery, or preferably employ a segmented temperature ramp: an initial 5 min at 70 °C followed by 15 min at 50 °C. The difference relative to Boc‑Pro‑OH, which decomposes detectably only above 100 °C in DMF, is attributed to the electron‑donating effect of the 2‑methyl group that slightly increases the electron density on the carbamate nitrogen, facilitating protonation and β‑elimination. This subtle disparity mandates dedicated thermal stability profiling whenever a synthetic route is transferred from Boc‑Pro to its α‑methyl analogue. For kilogram‑scale manufacturing of constrained peptide therapeutics where the N‑terminal Boc‑α‑Me‑Pro motif caps a linear sequence destined for macrocyclization, the hygroscopic nature of the compound and its susceptibility to lactam formation under acidic workup define the process boundary. After TFA‑mediated global deprotection and cleavage, the crude peptide is precipitated in cold diethyl ether and lyophilized from 0.1 % aqueous TFA. If the pH of the lyophilization solution exceeds 3.5, the free N‑terminal amine can cyclize onto the C‑terminal carboxyl to generate a diketopiperazine‑type byproduct with a characteristic mass loss of 18 Da; maintaining the solution at pH 2.0–2.5 with acetic acid suppresses this pathway. Purification by preparative RP‑HPLC (C18, 100 Å pore size, 10 µm particle, acetonitrile/water/0.1 % TFA) typically recovers the target peptide with a yield penalty of 5–8 % relative to the parent Boc‑Pro‑capped sequence, a trade‑off accepted for the gain in metabolic stability. Storage of the final lyophilized peptide at −20 °C under argon, with desiccant monitoring compliant with ICH Q1A(R2) guidelines, ensures 24‑month integrity when the solid remains below the glass transition temperature of trehalose‑based excipients frequently co‑lyophilized for formulation. In contrast, the Fmoc‑α‑Me‑Pro‑OH analogue, while obviating acid‑labile protecting group concerns, introduces a dibenzofulvene scavenging burden during large‑scale Fmoc removal and is generally reserved for sequences where orthogonal protecting group strategies demand base‑labile N‑protection. The Boc congener therefore occupies a distinct operational niche: processes that can tolerate a single global TFA treatment and benefit from the cost advantage of Boc chemistry on multi‑kilogram campaigns—documented in a 15‑kg campaign for a clinical‑stage NS3/4A protease inhibitor intermediate—favor the tert‑butoxycarbonyl variant provided that rigorous moisture exclusion and thermal control are enforced.